B44.1 Other pulmonary aspergillosis

Name of the Condition

• Other pulmonary aspergillosis

Summary

Other pulmonary aspergillosis refers to non-invasive or localized fungal infections of the lungs caused by Aspergillus species, distinct from invasive or allergic forms. The condition typically involves colonization or mild tissue involvement without systemic spread, often presenting with chronic or subacute symptoms. Clinical manifestations vary based on host immunity and underlying lung structure.

Causes

The condition is caused by Aspergillus species, common environmental molds. Spores are inhaled into the lungs, where they may colonize pre-existing cavities, bronchiectasis, or damaged tissue. Unlike invasive disease, the fungus does not invade blood vessels or spread systemically, but it can cause localized inflammation or structural changes in susceptible hosts.

Risk Factors

• Chronic lung diseases, such as bronchiectasis, sarcoidosis, or prior tuberculosis.
• Structural lung abnormalities, including cavities, bullae, or cysts.
• Prolonged corticosteroid use or mild immunosuppression.
• Environmental exposure to high Aspergillus spore concentrations.
• Prior lung surgery or trauma.

Symptoms

• Persistent cough, often with sputum production.
• Low-grade fever or malaise.
• Chest discomfort or mild shortness of breath.
• Hemoptysis (coughing up blood) in some cases.
• Weight loss or fatigue over weeks to months.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and microbiological testing. Chest imaging (e.g., CT) may show nodules, cavities, or bronchial wall thickening. Sputum or bronchial lavage cultures identify Aspergillus, while histopathology confirms tissue involvement. Allergy testing or serum markers may rule out allergic forms. Distinguishing from invasive disease requires assessing immune status and symptom progression.

Treatment Options

Treatment depends on severity and host factors. Antifungal therapy (e.g., azoles) is used for symptomatic or progressive cases. For localized disease, surgical resection may be considered. Underlying lung conditions (e.g., bronchiectasis) are managed to reduce fungal colonization. Allergic components, if present, may require corticosteroids or immunotherapy.

Prognosis and Follow-Up

Prognosis is generally favorable with appropriate treatment, especially in immunocompetent individuals. Chronic or recurrent cases may require long-term monitoring. Follow-up includes imaging to assess lesion stability and symptom resolution. Immunocompromised patients need closer surveillance for potential progression.

Complications

• Chronic lung damage or bronchiectasis.
• Hemoptysis from vascular involvement.
• Secondary bacterial infections.
• Progression to invasive aspergillosis in immunocompromised hosts.

Lifestyle & Prevention

• Avoid high-spore environments (e.g., construction sites, moldy areas).
• Manage underlying lung diseases to reduce susceptibility.
• Use air filtration in high-risk settings.
• Maintain good respiratory hygiene.

When to Seek Professional Help

Seek care for persistent respiratory symptoms, unexplained weight loss, or hemoptysis. Immunocompromised individuals should promptly report new or worsening cough, fever, or shortness of breath.

Tips for Medical Coders

Document the clinical context, including host immunity, imaging findings, and treatment response, to support the "other" designation. Differentiate from invasive or allergic forms using clinical details and diagnostic results. Ensure documentation aligns with the non-invasive, localized nature of the condition.